
Quintiles appoints Kevin Gordon finance chief
pharmafile | August 5, 2010 | Appointment | Research and Development | Quintiles, appointment, research and development
Pharmaceutical services company Quintiles has named Kevin Gordon chief financial officer.
He will have day-to-day responsibility for the company’s financial management and takes over from Mike Troullis, who moves into a senior corporate role managing Quintiles’ investments.
Kevin has spent over half of his 25-year career working for healthcare companies, and most recently served as chief financial officer at medical products company Teleflex.
“I am delighted to welcome Kevin to the Quintiles team,” said Quintiles chairman and chief executive Dennis Gillings. “His 13 years of health care experience provide a very solid footing and knowledge base for leading Quintiles’ financial organisation and building on our robust financial strategy.”
“Kevin joins us at a pivotal moment in Quintiles’ growth as we help our customers navigate the New Health, the rapidly morphing world of biopharma. His skills fit well with the business partnering model toward which our customers are moving. Kevin’s experience in business transformation will assist us in capitalizing on the opportunities that lie ahead,” Gillings added.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






